

Original
Indication:
CML

Additional
Approved
Indication

Not Approved

N/A

Untreated Adult Acute Myeloid Leukemia | NCT01806571

Acute Lymphoblastic Leukemia | NCT00844298

Adult Acute Lymphoblastic Leukemia in Remission | NCT00036738

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia | NCT01844765

CHRONIC MYELOGENOUS LEUKEMIA | NCT00760877

Myelogenous Leukemia Chronic | NCT00471497

Chronic Myelogenous Chronic | NCT00129740

Leukemia Myelogenous Leukemia | NCT01274351

Chronic Myelogenous Leukemia | NCT02272777

Chronic Myelogenous Leukemia | NCT01043674

Accelerated Phase Chronic Myelogenous Leukemia | NCT00702403

Chronic Myeloid Leukaemia | NCT01061177

Chronic Myeloid Leukemia | NCT01275196

Chronic Myeloid Leukemia | NCT01744665

Chronic Myeloid Leukemia | NCT01254188

Gastrointestinal Stromal Tumor (GIST) | NCT00785785

Gastrointestinal Stromal Tumors | NCT00471328

Mucosal Lentiginous Melanoma | NCT00788775

Melanoma | NCT010289028

Glioma | NCT01140588

Parkinson Disease | NCT03205488


Neurofibromatosis | NCT01275586

Systemic Sclerosis | NCT01166139

Nilotinib Indications in clinicaltrials.gov

Supplemental Figure 1

Dasatinib Indications in clinicaltrials.gov



Bosutinib Indications in clinicaltrials.gov

Leukemia Myelogenous Chronic Breakpoint Cluster Region Abelson Proto oncogene (BCR ABL) Positive | NCT02130557

Chronic Myelogenous Leukemia | NCT00811070

Chronic Myeloid Leukemia | NCT00281846

Chronic Myeloid Leukemia | NCT00574873

Advanced Malignant Solid Tumors | NCT00195260

Breast Neoplasms | NCT00319254

Glioblastoma | NCT01331291

Polyzystic Kidney Autosomal Dominant | NCT01233869

Original
Indication:
CML

Additional
Approved
Indication

Not Approved

N/A

Ponatinib Indications in clinicaltrials.gov

Original
Indication:
CML

Additional
Approved
Indication

Not Approved

N/A

Height

Non Small Cell Lung Cancer | NCT01813734

Malignant Hepatobiliary Neoplasm | NCT02265341

Chronic Myeloid Leukemia | NCT01207440

Glioblastoma | NCT02478164

Gastrointestinal Stromal Tumor | NCT01874665

Indications


Imatinib Indications in clinicaltrials.gov

Original Indication: **NSCLC**

Additional Approved Indication


Not Approved

IA



Histological or Cytological Diagnosis of Locally

Gefitinib Indications in clinicaltrials.gov





Afatinib Indications in clinicaltrials.gov

Original
Indication:
NSCLC


Additional
Approved
Indication

Not Approved

N/A



Brigatinib Indications in clinicaltrials.gov



Original
Indication:
NSCLC

Additional
Approved
Indication

Not Approved

N/A


Sunitinib Indications in clinicaltrials.gov

Original
Indication:
GIST & RCC

Additional
Approved
Indication

Not Approved

N/A



Osimertinib Indications in clinicaltrials.gov

Original
Indication:
NSCLC

Additional
Approved
Indication

Not Approved

N/A

Healthy Volunteer | NCT02224053

Healthy Volunteers | NCT02098679

Healthy Volunteers | NCT02491944

Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB IV) | NCT02179671

Carcinoma Non Small Cell Lung With EGFR Mutation Positive | NCT02529995

Carcinoma Non Small Cell Lung | NCT03370770

Non Small Cell Lung Cancer | NCT02317016